




Searching News Database: targeted oncology
HSMN NewsFeed - 4 May 2021
Theseus Pharmaceuticals Appoints Tim Clackson, Ph.D., as Chief Executive Officer
Theseus Pharmaceuticals Appoints Tim Clackson, Ph.D., as Chief Executive Officer
HSMN NewsFeed - 13 Apr 2021
Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors
Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors
HSMN NewsFeed - 26 Oct 2020
Jazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program
Jazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program
HSMN NewsFeed - 8 Nov 2018
Mr. Matthew Dallas and Mr. Jeffrey Young Appointed to Biostage Board of Directors
Mr. Matthew Dallas and Mr. Jeffrey Young Appointed to Biostage Board of Directors
HSMN NewsFeed - 7 Aug 2018
Infinity Pharmaceuticals Appoints Samuel Agresta, M.D., M.P.H. as Chief Medical Officer
Infinity Pharmaceuticals Appoints Samuel Agresta, M.D., M.P.H. as Chief Medical Officer
HSMN NewsFeed - 5 Aug 2015
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
HSMN NewsFeed - 21 Aug 2014
Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer
Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer
HSMN NewsFeed - 4 Dec 2012
Galena Biopharma Announces Signature of Commercialization Partnership With Teva for Israel
Galena Biopharma Announces Signature of Commercialization Partnership With Teva for Israel
HSMN NewsFeed - 8 Nov 2011
Curis Announces Appointment of Maurizio Voi, M.D. as Chief Medical and Chief Development Officer
Curis Announces Appointment of Maurizio Voi, M.D. as Chief Medical and Chief Development Officer
HSMN NewsFeed - 4 Oct 2011
Galena Biopharma Hires Hana B. Moran as Vice President, Regulatory Affairs and Compliance
Galena Biopharma Hires Hana B. Moran as Vice President, Regulatory Affairs and Compliance
HSMN NewsFeed - 30 Aug 2007
OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
Additional items found! 24

Members Archive contains
24 additional stories matching:
targeted oncology
(Password required)
targeted oncology
(Password required)